ストックスクリーナーアプリを入手
744.43
0.04%
-1.08
前日終値:
$743.35
開ける：
$744.87
24時間の取引高:
127.11K
Relative Volume:
0.20
時価総額：
$81.65B
収益：
$13.85B
当期純損益:
$4.65B
株価収益率:
21.23
EPS:
35.06
ネットキャッシュフロー:
$3.32B
1週間 パフォーマンス:
-5.05%
1か月 パフォーマンス:
-23.28%
6か月 パフォーマンス:
-25.24%
1年 パフォーマンス:
-6.99%
1日の値動き範囲:
$735.95
$746.86
1週間の範囲:
$735.95
$783.10
52週間の値動き範囲:
$735.95
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
名前
Regeneron Pharmaceuticals Inc
セクター
電話
(914) 847-7000
住所
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| REGN | 745.70 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| VRTX | 448.57 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| ARGX | 589.40 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.98 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.47 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 繰り返されました | Oppenheimer | Perform |
| 2023-06-28 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-23 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | アップグレード | Cowen | Market Perform → Outperform |
| 2023-01-20 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-09-09 | アップグレード | Jefferies | Underperform → Hold |
| 2022-09-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 開始されました | Jefferies | Underperform |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-03 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-12-07 | 再開されました | Cowen | Market Perform |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 再開されました | BMO Capital Markets | Outperform |
| 2021-11-05 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-01-25 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-01-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-10-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-07-09 | アップグレード | SunTrust | Hold → Buy |
| 2020-05-26 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-17 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 開始されました | The Benchmark Company | Hold |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-02-26 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-11 | アップグレード | Argus | Hold → Buy |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-16 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-12-13 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Hold |
| 2019-11-07 | アップグレード | Citigroup | Neutral → Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
すべてを表示
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Connor Clark & Lunn Investment Management Ltd. Has $21.56 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
(REGN) On The My Stocks Page - Stock Traders Daily
Multiple Myeloma Market on Track for Major Expansion by 2034, According to DelveInsight | Janssen Pharma, Regeneron Pharma, Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron - Barchart
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Myopic Macular Degeneration Market Forecasted to Surge - openPR
Retireful LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Multiple Myeloma Market on Track for Major Expansion by 2034, - openPR
Breakthrough Therapy BT Designation Market Is Booming - openPR
Artery Stenosis Drug Market Insights Comprehensive Trends, - openPR
Retinal Biologics Market: Future Scope, Growth Potential, - openPR
Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now - Insider Monkey
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Regeneron: The Biotech Stock To Buy Now (NASDAQ:REGN) - Seeking Alpha
Eczema Therapeutics Market 2024-2031 Revenues Will Increase - openPR
10 Best Genomics Stocks To Buy Right Now - Insider Monkey
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking - Benzinga
Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3 - Insider Monkey
Familial Hypercholesterolemia Market Forecasted to Surge - openPR
Quest Partners LLC Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Macular Degeneration Treatment Market Is Expected To Reach - openPR
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
10 Biggest Biotechnology Companies - Investopedia
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria - Nasdaq
Regeneron Says Samsung Eye Med Biosimilar Will Infringe IP - Law360
Peering Into Regeneron Pharmaceuticals's Recent Short Interest - Benzinga
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Braun Stacey Associates Inc. - MarketBeat
Cutaneous Squamous Cell Carcinoma Market Geographical - openPR
2 Top Growth Stocks to Buy on the Dip - AOL
Swiss National Bank Acquires 2,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Seizert Capital Partners LLC - MarketBeat
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis - GlobeNewswire Inc.
Mizuho Securities USA LLC Acquires 51,162 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by CIBC Asset Management Inc - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wolfe Research - MarketBeat
Rep. Greg Landsman Sells Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock - MarketBeat
Citigroup Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Neutral Recommendation - MSN
Regeneron to “vigorously defend” against DOJ on Eylea pricing complaint - MSN
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria - Pharmaceutical Technology
Simplify Asset Management Inc. Purchases 3,231 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Check Out What Whales Are Doing With REGN - Benzinga
Regeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated at Wolfe Research - MarketBeat
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease - Benzinga
Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S. - Seeking Alpha
ING Groep NV Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
FDA to review Sanofi, Regeneron’s Dupixent sBLA for CSU - Pharmaceutical Business Review
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Citigroup - MarketBeat
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU - MarketWatch
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - GlobeNewswire
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous - The Bakersfield Californian
Regeneron Pharmaceuticals Inc (REGN) 財務データ
収益
当期純利益
現金流量
EPS
0.34%
0.09%
大文字化:
|
ボリューム (24 時間):